Details:
Leqembi (lecanemab-irmb) is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta (Aβ). It is indicated for the treatment of Alzheimer’s disease.
Lead Product(s): Lecanemab-irmb
Therapeutic Area: Neurology Product Name: Leqembi
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 09, 2024
Details:
Through the acquisition, Navamedic will broaden its product portfolio, including Flexilev, containing two active substances, levodopa and carbidopa and to support patients suffering from medical conditions, such as Parkinson's disease.
Lead Product(s): Etilevodopa,Carbidopa
Therapeutic Area: Neurology Product Name: Flexilev
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Navamedic
Deal Size: $9.3 million Upfront Cash: $9.3 million
Deal Type: Acquisition April 24, 2023
Details:
Through the acquisition, Navamedic will broaden its product portfolio and to support patients suffering from medical conditions, such as Parkinson's disease, including Flexilev, containing two active substances, levodopa and carbidopa.
Lead Product(s): Etilevodopa,Carbidopa
Therapeutic Area: Neurology Product Name: Flexilev
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Navamedic
Deal Size: $7.2 million Upfront Cash: $7.2 million
Deal Type: Acquisition March 29, 2023
Details:
Leqembi (lecanemab-irmb) is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta (Aβ). It is indicated for the treatment of Alzheimer’s disease.
Lead Product(s): Lecanemab-irmb
Therapeutic Area: Neurology Product Name: Leqembi
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 27, 2023
Details:
Fresenius Kabi Lacosamide Injection, USP is an approved treatment option for partial-onset seizures in patients 17 years of age and older and is available in 200 mg per 20 mL single-dose vials.
Lead Product(s): Lacosamide
Therapeutic Area: Neurology Product Name: Lacosamide-Generic
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 15, 2022
Details:
In review of marketing authorisation application (MAA) for NEFECON, the CHMP has informed that they will issue an additional list of questions related to manufacturing-related information which will result in the opinion from EMA slipping into the second quarter.
Lead Product(s): Budesonide
Therapeutic Area: Neurology Product Name: Nefecon
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 22, 2022
Details:
Company received IND clearance from the USFDA to initiate phase III pivotal clinical trials with its combination registration of medical device Sedaconda ACD and pharmaceutical Sedaconda (isoflurane) for sedation of mechanically ventilated intensive care patients.
Lead Product(s): Isoflurane
Therapeutic Area: Neurology Product Name: Sedaconda
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 23, 2021
Details:
By acquiring Lobsor Pharmaceuticals, STADA gains rights to a triple fixed combination (levodopa, carbidopa, entacapone), delivered via modern pump technology, that has already been successfully launched in Nordic countries.
Lead Product(s): Etilevodopa,Carbidopa,Entacapone
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: STADA Arzneimittel
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition October 02, 2020
Details:
The new agreement provides both companies with a long-term partnership that will ensure continued supply for patients across the globe. Opicapone (Ongentys) is approved in Europe, USA, South Korea, Taiwan, Australia and Japan.
Lead Product(s): Opicapone
Therapeutic Area: Neurology Product Name: Ongentys
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Bial
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement October 01, 2020